A Phase III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (ECOG-ACRIN E4512)
This phase III ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Salvatore Del Prete, MD
Sponsor(s)National Cancer Institute
ContactEd Hatton, RN at 203-358-8879 or [email protected]
Bennett Cancer Center
Stamford, CT 06902